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Abstract
Purpose The risk of scalp metastases in patients using
scalp cooling for preservation of hair during chemotherapy
has been a concern but is poorly described.
Methods A systematic review and meta-analysis of longi-
tudinal studies was undertaken to evaluate the effect of
scalp cooling versus no scalp cooling on the risk of scalp
metastasis in patients treated for breast cancer with
chemotherapy. Electronic databases, journal specific, and
hand searches of articles identified were searched. Patients
were matched based on disease, treatment, lack of meta-
static disease, and sex.
Results A total of 24 full-text articles were identified for
review. Of these articles, ten quantified the incidence of
scalp metastasis with scalp cooling over time. For scalp
cooling, 1959 patients were evaluated over an estimated
mean time frame of 43.1 months. For no scalp cooling,
1238 patients were evaluated over an estimated mean time
frame of 87.4 months. The incidence rate of scalp metas-
tasis in the scalp cooling group versus the no scalp cooling
group was 0.61% (95% CI 0.32–1.1%) versus 0.41% (95%
CI 0.13–0.94%); P = 0.43.
Conclusion The incidence of scalp metastases was low
regardless of scalp cooling. This analysis suggests that
scalp cooling does not increase the incidence of scalp
metastases.
Keywords Scalp metastasis  Scalp cooling  Breast cancer
Introduction
Breast cancer is a common malignancy in the western
world; it is estimated that more than 246,660 women in the
USA will be diagnosed in 2016 with this disease [1, 2].
Most of these women are treated surgically with curative
intent, although neoadjuvant chemotherapy may be given
first to improve surgical options. Adjuvant therapy
including hormonal and chemotherapy, as well as local
radiation therapy, is a commonly used modality following
definitive surgery to reduce the risk of local and systemic
recurrence. Adjuvant chemotherapy has been shown to
delay or prevent recurrence in early-stage breast cancer,
and recent studies as well as ongoing work are helping to
define the group of patients who are most likely to benefit
from this treatment [3, 4]. A cancer diagnosis is psycho-
logically distressing, and decisions about adjuvant therapy
compound this distress. Alopecia is a disturbing side effect
of almost all effective adjuvant chemotherapy regimens.
Chemotherapy is associated with a number of toxicities,
but alopecia is the most publicly visible sign of this treat-
ment with psychological impact [5–8]. Scalp cooling to
prevent chemotherapy-induced alopecia has been in use
since the 1970s, and was recently cleared for marketing in
the United States [9]. Existing and emerging data have
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demonstrated excellent or good prevention of alopecia
caused by commonly used chemotherapeutic regimens
[10]. The protection from alopecia offered by scalp cooling
is thought to be due to both vasoconstriction resulting in
reduced blood flow in the scalp, and reduced metabolic rate
in the hair follicles [6].
The primary concern that has limited the use of scalp
cooling devices in the United States is the possibility that
scalp cooling could increase the risk for scalp metastases
[10]. Scalp metastases are a rare site of metastatic disease
in breast cancer [11, 12].
A recent review of the literature on scalp metastasis
following adjuvant chemotherapy for early-stage breast
cancer [13] found it unlikely that the incidence of scalp
metastasis might increase after scalp cooling. However,
this study reviewed the incidence of both skin and scalp
metastasis with and without adjuvant chemotherapy in
patients with early- and late-stage breast cancer as well as
other cancers, and with highly variable follow-up, which
included patients on whom the follow-up time was not
identified.
The intent of this systematic review and meta-analysis is
to examine the effect of scalp cooling versus no scalp
cooling on the incidence of scalp metastasis in patients
being treating for breast cancer with adjuvant chemother-
apy with identified follow-up.
Methods
A systematic review of the literature was undertaken using
the following search terms: chemotherapy AND breast
cancer AND scalp metastas*.
The following electronic databases were searched:
• PubMed (searched on October 13, 2016 & February 15,
2017)
• Google (searched on October 13, 2106 & February 15,
2017; first 4 pages of hits)
The following online journals were searched:
• Breast Cancer Research and Treatment (searched on
October 13, 2016 & February 15, 2017)
• Supportive Care in Cancer (searched on October 13,
2016 & February 15, 2017)
• European Journal Oncology Nursing (searched on
October 13, 2016 & February 15, 2017)
• European Journal Cancer (searched on October 13,
2016 & February 15, 2017)
• Journal Clinical Oncology (searched on October 13,
2016 & February15, 2017).
Hand searches of all articles included in the analysis
were undertaken on October 14–15, 2016 & February
16–17, 2017.
Two authors independently reviewed each of the studies
and used a data collection form to determine inclusion
eligibility (see Appendix 1). A third author acted as arbiter
in those situations where disagreement existed between the
first two authors.
Inclusion criteria used in the qualitative
and quantitative (meta-analysis) review
Articles which evaluated patients treated for breast cancer
with chemotherapy and, with and without the use of scalp
cooling technology and, examined the longer-term seque-
lae of this therapy (with identified follow-up timeframes)
including scalp metastasis were included in this analysis.
Exclusion criteria used
Patients who had other types of early-stage cancers, studies
that did not examine longer-term sequelae (i.e., only
reported on the immediate short term results of the cancer
treatment), and studies including patients who were not
treated with chemotherapy were excluded from the
analysis.
Statistical analysis
MedCalc statistical software (Version 16.8.4) was used to
calculate the incidence rates and confidence intervals of the
combined studies with and without the use of scalp cooling
over time. A P value was then calculated to determine if
there were a statistically meaningful difference between the
two rates. A weighted (weighted based on the number of
patients in each trial) average of the follow-up durations
was then calculated along with standard deviations.
Results
Figure 1 shows the identification, screening, eligibility, and
inclusion as part of the systematic review. A total of 24
full-text studies were identified as eligible for review.
Included studies
Ten studies which reported on scalp metastasis were
included in the analysis, of which five reported on scalp
cooling only [13–17], four reported on scalp cooling versus
no scalp cooling [11, 18–20], and one on no scalp cooling
[12] (Table 1).
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Excluded studies
Fourteen studies were excluded for the following reasons:
No follow-up or unclear follow-up time following com-
pletion of chemotherapy (total of 10) [21–30]; patients
used scalp cooling for treatment of metastatic disease (total
of 2) [31, 32]; treatment for breast cancer was not specified
(one study) [33]; and one study was excluded due to
unclear cancer type at presentation [34] (Table 2).
Effect of scalp cooling vs non-scalp cooling
on the outcome of scalp metastasis
There were 12 cases of scalp metastases out of 1959
patients where scalp cooling was employed (Table 1). The
incidence rate was 0.61% (95% CI 0.32–1.1%). These
patients were followed for an estimated mean of
43.14 months (weighted mean average). There were 5
cases of scalp metastasis out of 1238 patients where scalp
cooling was not used (Table 1). The incidence rate was
0.4% (95% CI 0.13–0.9%). These patients were followed
for an estimated mean of 87.4 months (weighted mean
average). There was no statistically meaningful difference
between the two comparison groups (with and without
scalp cooling) (P = 0.43).
Discussion
The possibility that scalp cooling protects the scalp from
the beneficial effects of adjuvant chemotherapy has been a
concern that has limited the use of these devices in the
United States. However, this systematic review and meta-
analysis examining patients with breast cancer receiving
chemotherapy while using scalp cooling for hair preser-
vation does not support this concern and, demonstrates no
statistical difference in the incidence of scalp metastasis
between patients using scalp cooling vs. no scalp cooling.
This analysis further complements the van den Hurk 2013
study [13] (which also found no statistically meaningful
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difference) and adds additional longer-term study data
(with confirmed duration of follow-up of breast cancer
specifically to identify scalp metastasis) to further sub-
stantiate the low incidence of scalp metastases [15, 18, 35].
Scalp metastases occur rarely in breast cancer (with
metastases more commonly occurring in other areas of skin
including chest wall [36]) and, as reviewed above, scalp
metastases seem to accompany and usually occur following
the diagnosis of widespread metastatic disease. Interest-
ingly, in a sensitivity analysis which added back those
studies that were excluded due to no mention of follow-up
time and/or type of cancer treatment but where breast
cancer was identified as the primary source, scalp cooling
and no scalp cooling were identified, no other metastatic
cancer was present, and scalp metastases were identified
[22, 24–26, 29, 33]; a statistically significant difference in
the incidence of scalp cooling between scalp cooling and
no scalp cooling was found [11–20] (scalp cooling inci-
dence 0.4%; 95% CI 0.21–0.66% vs. no scalp cooling:
1.2%; 95% CI 0.75–1.8%; P = 0.006).
Table 1 Included Studies
Study Scalp cooling No scalp
cooling
Length of
follow-up
(months)
scalp
cooling
median
Weighted
length of
follow-up
scalp
cooling
Length of
follow-up
(months)
no scalp
cooling
median
Weighted
length of
follow-up
no scalp
cooling
Characteristics
Scalp
mets
Total
pts
Scalp
mets
Total
pats
Lemieux
et al. [11]
6 553 1 87 69 19.478 64 4.498 First time breast cancer patients. Study
undertaken in Canada. Mainly T1 and
T2 tumor size; stage 1 & 2, treated with
mainly cyclophosphamides and
doxorubicin
Parker [14] 0 6 12 0.037 Stage 4 recurrent disease. Treated with
IV CMF (2 cycles)
Protiere
et al. [18]
0 77 0 109 44 1.729 First time breast cancer patients. 4 cycles
of adjuvant IV chemotherapy with
mitoxantrone ? cyclophosphamide.
Antiemetics also administered. Study
undertaken in France
Ridderheim
[15]
0 3 15 0.023 Adjuvant treatment breast cancer
Ron et al.
[19]
0 19 0 16 14 0.136 14 0.181 Breast cancer patients treated with
cyclophosphamide, methotrexate, and
5- fluorouracil [CMF]; unclear as to
stage of breast cancer
Rugo [17] 0 101 29.5 1.521 Early-stage breast cancer patients
Spae¨th et al.
[20]
3 770 0 141 36 14.150 36 4.100 93% breast cancer patients. Treated with
IV chemo mainly anthracyclines and/or
taxotere. Unclear as to stage of breast
cancer
Tollenaar
et al. [35]
0 35 46 0.822 Patients treated with
cyclophosphamide ? doxorubicin ? 5-
fluorouracil on first operative day (one
course of treatment). Unclear as to
stage of cancer
van de
Sande [12]
4 885 110 78.635 Stage 4 ? lymph nodes
van den
Hurk et al.
[13]
3 395 26 5.242 treated with CMF; unclear as to stage of
breast cancer
Totals 12 1959 5 1238
Averages 32.39 43.14 56 87.41
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Additional questions considered
Does adjuvant chemotherapy reduce the risk for scalp
metastases in breast cancer patients? The ability of adju-
vant chemotherapy to specifically reduce scalp metastases
presumes that there are dormant micrometastatic cells
already seeded in the scalp from the primary tumor at the
time of diagnosis of early-stage disease. However, it is
much more likely that adjuvant chemotherapy effects
occult metastatic cells in other sites that might eventually
metastasize to the scalp [37], as this site (scalp) of meta-
static disease is uncommon.
Does scalp cooling increase the incidence of scalp
metastases as the first sign of recurrent breast cancer? Scalp
metastases are very rarely reported as the first site of
metastatic recurrence in patients with early-stage breast
cancer. The National Surgical Adjuvant Breast and Bowel
Project (NSABP) reported in a communication to Judith
Dean [38] that two patients in a sample of 7800 women had
metastases to scalp as the first site of recurrent disease. One
of these patients had received adjuvant chemotherapy. The
incidence of scalp metastases as the first site of recurrence
can therefore be estimated to be around 0.025% (2/7800).
Is it possible that scalp cooling used in conjunction with
adjuvant chemotherapy increases the risk for scalp metas-
tases as the site for first recurrence? Based on available
data, this appears to be highly unlikely. Two cases of scalp
metastases as the first detected metastatic site in patients
with breast cancer previously treated with adjuvant
chemotherapy together with scalp cooling were described
by Lemieux [39]. The first patient presented with a scalp
metastasis as the first site of metastatic disease 9 years
following breast cancer chemotherapy, but had only used
scalp cooling during 2 of 4 cycles of doxorubicin and
cyclophosphamide. Many other sites of metastases were
found in this patient a few months later. The second patient
used scalp cooling in only one out of 6 cycles of adjuvant
cyclophosphamide, methotrexate, and 5-fluorouracil, and
then was treated for a local recurrence 5 years later with
surgery and 6 cycles of epirubicin 100 mg/m2 without
scalp cooling. It is highly unlikely that scalp cooling used
in one out of 12 chemotherapy cycles in this patient at high
Table 2 Studies excluded with reasons
Study Reason for exclusion
Christodoulou
[21]
Zero out of 30 breast cancer patients developed a scalp metastasis. However, there was no mention of the follow-up time in
this patient cohort. Scalp cooling was employed
Campos-Gomez
[23]
Sixty-eight patients in scalp cooling were reported as followed up on, but it was unclear as to the timeframe of follow-up. No
mention as well of scalp metastasis
Christodoulou
[22]
Two out of 227 breast cancer patients developed scalp metastasis. However, there was no mention of the follow-up time in
this patient cohort. Scalp cooling was employed
Dean [24] Fifty-eight breast cancer patients treated with doxorubicin and with scalp cooling were reported on for scalp metastasis, but
there was no mention of the follow-up time
Johansen [31] One patient in scalp cooling group who already had metastatic breast cancer (in the liver) experienced scalp metastasis
(n = 61); all patients in group already had metastatic primary or recurrent cancer originating from the breast
Kargar [34] Unclear as to type of primary cancer patients had
Lemenager [32] Breast cancer patients treated with chemotherapy (n = 88); all had metastatic disease and were treated with scalp
hypothermia. No mention of scalp metastasis
Lookingbill [33] No mention of how patients with breast cancer were treated; There were 18 patients with scalp metastases out of 707
primary breast cancer patients. (18/707 = 2.5%). There was also no mention of the follow-up time as to when scalp
metastases occurred
Massey [25] Breast cancer patients treated with chemotherapy (n = 94) treated with Paxman cooling system. None of these patients
developed scalp metastases during the study period. Unclear as to the length of follow-up on these patients
Middleton et al.
[26]
Twenty-four patients with breast cancer receiving adjuvant chemotherapy. No length of follow-up noted. No scalp
metastases noted
Nangia et al. [30] No long-term follow-up on patients in randomized controlled trial
Peck et al. [27] One patient in scalp cooling group subsequently presented with scalp metastasis. However, patient already had widespread
metastatic cancer (n = 10); unclear as to follow-up
Satterwhite [28] One patient in scalp cooling group already had scalp metastasis (n = 12); no follow-up
van den Hurk [29] Breast cancer patients treated with chemotherapy in the Dutch scalp cooling registry (n = 1216). No patients developed
scalp metastasis during the study period of 2006–2009. However, unclear as to the length of follow-up on these patients
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risk for recurrent disease contributed to the finding of a
scalp metastasis 7 years after her initial diagnosis. In both
cases, it is quite unlikely that there is any association of
scalp cooling with subsequent development of a scalp
metastasis.
Considering the exceedingly low incidence of scalp
metastasis as a first site of recurrence (or in general), the
risk appears small for scalp cooling to increase the inci-
dence of scalp metastases in patients with breast cancer. In
addition, the concept that scalp cooling could increase the
incidence of metastases to the scalp suggests dormant cells
in the scalp are responsible for recurrence—again unlikely.
Based on what is now understood about the biology of
breast cancer, and the low incidence of scalp metastases as
the site of first recurrence, it is very unlikely that scalp
cooling contributes to the risk of metastatic recurrence.
Study limitations
The analysis undertaken was retrospective in nature. As
well, most studies did not examine scalp metastasis as a
primary endpoint. These types of studies have inherent
biases.
The scalp cooling comparison arm (n = 1,959) evalu-
ated patients over an estimated weighted mean of
42.1 months versus an estimated weighted mean of
87.4 months for non-scalped-cooled patients. The
assumption in calculating these weighted mean averages
was that the distributions from which the sample means
came from were relatively normal (bell-shaped and sym-
metric). Further, since the sample sizes of several of the
studies evaluated were large [7, 11–13, 17, 18] (comprising
over 98% of the patients evaluated), the median and mean
were assumed to be fairly close in value. Based on these
factors, we believe the weighted mean value is a reasonable
approximation of the follow-up timeframes. Follow-up on
scalp cooling patients over a longer period of time is
ongoing [17, 30].
Conclusion
Based on this extensive review and meta-analysis, scalp
cooling is highly unlikely to increase the incidence of scalp
metastases in patients with early-stage breast cancer
receiving adjuvant chemotherapy. Van den Hurk 2013 [13]
stated: ‘‘We found it rather unlikely that the incidence of
scalp metastases might increase at all after scalp cooling
and; that a very small proportion of patients receiving
chemotherapy (with or without scalp cooling) are at risk for
developing metastases at this site.’’ Based on this analysis,
we would concur with van den Hurk.
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